inarem vial inj
emcure - doripenem - inj - 1g - vial
inarem vial inj
emcure - doripenem - inj - 250mg - vial
zavicefta powder for concentrate for solution for infusion 2g0.5g
pfizer private limited - avibactam sodium 543.5 mg eqv. to avibactam; ceftazidime pentahydrate 2329.7 mg eqv. to ceftazidime - injection, powder, for solution - avibactam sodium 543.5 mg eqv. to avibactam 500mg; ceftazidime pentahydrate 2329.7 mg eqv. to ceftazidime 2g
biomerieux etest antimicrobial susceptibility testing
biomerieux singapore pte. ltd. - clinical chemistry - etest® is a manual, quantitative technique for the determination of antimicrobial susceptibility of non‑fastidious gram‑negative and gram‑positive aerobic bacteria and fastidious bacteria and yeasts and mould. the system comprises a predefined antibiotic gradient which is used to determine the minimum inhibitory concentration (mic, in μg/ml) of different antimicrobial agents against microorganisms tested on agar media after overnight incubation.
zavicefta (ceftazidime 2gavibactam 0.5g) powder for concentrate for solution for infusion
pfizer (malaysia) sdn. bhd. - avibactam sodium; ceftazidime pentahydrate -
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials for systemic use, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.consideration should be given to official guidance on the appropriate use of antibacterial agents.
depakene solution
bgp pharma ulc - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants
epival tablet (delayed-release)
bgp pharma ulc - valproic acid (divalproex sodium) - tablet (delayed-release) - 125mg - valproic acid (divalproex sodium) 125mg - miscellaneous anticonvulsants
epival tablet (delayed-release)
bgp pharma ulc - valproic acid (divalproex sodium) - tablet (delayed-release) - 250mg - valproic acid (divalproex sodium) 250mg - miscellaneous anticonvulsants
novo-valproic capsule
teva canada limited - valproic acid - capsule - 250mg - valproic acid 250mg - miscellaneous anticonvulsants